Review
Nanoscience & Nanotechnology
Ana Cepero, Cristina Luque, Laura Cabeza, Gloria Perazzoli, Francisco Quinonero, Cristina Mesas, Consolacion Melguizo, Jose Prados
Summary: The development of delivery systems based on nanomaterials, conjugated with monoclonal antibodies, shows promise in improving the efficiency and effectiveness of colorectal cancer therapy.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2022)
Review
Health Care Sciences & Services
Christopher Chang-Yew Leow, Michael Sze Yuan Low
Summary: Despite advancements in therapies such as proteasome inhibitors and immunomodulatory drugs, multiple myeloma remains a challenging and relapsing disease with no cure in sight. Over the past decade, novel drugs targeting essential cellular proteins and anti-apoptotic, ribosomal, and nuclear export proteins have emerged as potential treatments against malignant plasma cells.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Immunology
Yingnan Si, Ya Zhang, Jia-Shiung Guan, Hanh Giai Ngo, Angela Totoro, Ajeet Pal Singh, Kai Chen, Yuanxin Xu, Eddy S. Yang, Lufang Zhou, Runhua Liu, Xiaoguang (Margaret) Liu
Summary: Targeting CD47 with a monoclonal antibody shows great potential in treating TNBC with high specificity. The antibody-drug conjugate demonstrated higher potency in TNBC cells compared to free drugs and significantly inhibited tumor growth. Whole blood analysis indicated no general immune toxicity of the anti-CD47 mAb.
Article
Cell Biology
Jiashuai Zhang, Zhuoxin (Zora) Zhou, Kai Chen, Seulhee Kim, Irene Soohyun Cho, Tanvi Varadkar, Hailey Baker, Ju Hwan Cho, Lufang Zhou, Xiaoguang (Margaret) Liu
Summary: The study found that anti-CD276 ADC could be a promising candidate for NSCLC treatment, showing high surface binding and tumor-specific targeting, and demonstrating good anti-tumor efficacy in models.
Article
Immunology
Basudev Paudyal, Adam McNee, Pramila Rijal, B. Veronica Carr, Alejandro Nunez, John McCauley, Rodney S. Daniels, Alain R. Townsend, John A. Hammond, Elma Tchilian
Summary: Prophylactic intravenous administration of specific monoclonal antibodies in pigs showed significant reduction in lung pathology and virus loads, but not consistent reduction in nasal shedding. The effect on lung pathology and virus load is consistent across different doses, suggesting that lower doses may be effective in reducing disease severity.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Victor Albarran, Diana Isabel Rosero, Jesus Chamorro, Javier Pozas, Maria San Roman, Ana Maria Barrill, Victor Alia, Pilar Sotoca, Patricia Guerrero, Juan Carlos Calvo, Inmaculada Orejana, Patricia Perez de Aguado, Pablo Gajate
Summary: Metastatic urothelial cancer is a major cause of cancer-related death, but new treatment approaches targeting Her-2 show promise, especially with the emergence of antibody-drug conjugates as a novel therapy for advanced cases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Multidisciplinary Sciences
Sung Chang Lee, Jennifer S. Y. Ma, Min Soo Kim, Eduardo Laborda, Sei-Hyun Choi, Eric N. Hampton, Hwayoung Yun, Vanessa Nunez, Michelle T. Muldong, Christina N. Wu, Wenxue Ma, Anna A. Kulidjian, Christopher J. Kane, Vadim Klyushnichenko, Ashley K. Woods, Sean B. Joseph, Mike Petrassi, John Wisler, Jing Li, Christina A. M. Jamieson, Peter G. Schultz, Chan Hyuk Kim, Travis S. Young
Summary: The study introduced a unique semisynthetic bispecific antibody, CCW702, which showed specific and potent in vitro cytotoxicity, good tolerability and subcutaneous bioavailability in mice and cynomolgus monkeys, supporting a weekly dosing regimen testing in patients.
Review
Oncology
Weiling Li, Xiaoling Zhang, Yunyi Du, Ying Zhang, Jing Lu, Wenqing Hu, Jun Zhao
Summary: The incidence of gastric/gastroesophageal junction (G/GEJ) cancer remains high globally, especially in China. Patients with early-stage G/GEJ adenocarcinoma have a better prognosis after surgery, while those with advanced metastatic G/GEJ adenocarcinoma have a less optimistic long-term survival outlook. The identification of various biomarkers, particularly microsatellite instability (MSI), programmed cell death-ligand 1 (PD-L1), human epidermal growth factor receptor 2 (HER2), tumor mutational burden (TMB), and Epstein-Barr virus (EBV), has significantly improved the clinical efficacy of treatments for G/GEJ adenocarcinoma by identifying targeted populations. HER2-targeted therapy has shown excellent clinical outcomes for patients with advanced HER2-positive G/GEJ adenocarcinoma, although some patients develop resistance.
BIOMARKER RESEARCH
(2022)
Article
Polymer Science
Ya-Kui Huang, Hong-Rui Tian, Ming-Zu Zhang, Jin-Lin He, Jian Liu, Pei-Hong Ni
Summary: This study developed a monoclonal antibody and a polymer-hyd-doxorubicin prodrug conjugate to achieve precise targeting, tumor tissue aggregation, and pH-sensitive drug release of self-assembled nanoparticles. The nanoparticles with antibodies exhibited higher cytotoxicity and relatively better stability, showing potential for targeted drug delivery through CD147 monoclonal antibody.
CHINESE JOURNAL OF POLYMER SCIENCE
(2021)
Article
Biochemical Research Methods
Xiumin Shi, Qing Li, Lulu Zhang, Masayuki Hanyu, Lin Xie, Kuan Hu, Kotaro Nagatsu, Chuan Zhang, Zhengcan Wu, Feng Wang, Ming-Rong Zhang, Kai Yang, Ran Zhu
Summary: The study developed a novel semiconducting polymer nanoparticle-based radiopharmaceutical for targeted radionuclide therapy against GIPR-positive cancers, showing high therapeutic efficiency and biological safety in cell and mouse models.
BIOCONJUGATE CHEMISTRY
(2021)
Article
Oncology
Si -Yang Liu, Jia-Tao Zhang, Kang-Hui Zeng, Yi-Long Wu
Summary: Targeted therapy has revolutionized the perioperative treatment of early-stage oncogene-driven NSCLC, with clinical trials focusing on EGFR mutations showing promising results. Further studies are needed to evaluate biomarker selection and other parameters to optimize treatment strategies.
Review
Hematology
Sabine Kayser, Mark J. Levis
Summary: Research on the pathogenic mechanisms of AML has made remarkable advances in recent years, especially in the importance of cytogenetic and molecular aberrations. The development of new compounds targeting AML at a molecular level, based on increased understanding of AML pathogenesis facilitated by next-generation sequencing, has turned many hopeful predictions into therapeutic realities.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Review
Oncology
Andrew B. Katims, Peter A. Reisz, Lucas Nogueira, Hong Truong, Andrew T. Lenis, Eugene J. Pietzak, Kwanghee Kim, Jonathan A. Coleman
Summary: Urothelial carcinoma is a malignancy with poor prognosis. The standard treatment is chemotherapy followed by immunotherapy, but the survival outcomes are still unsatisfactory. New targeted therapies have been identified and shown efficacy as second-line treatment, which can be extended to other treatment categories.
Article
Pharmacology & Pharmacy
O. Ngozi Nwaefulu, S. Rao Sagineedu, M. Kaisarul Islam, J. Stanslas
Summary: Pancreatic cancer is a difficult-to-treat disease with a high fatality rate. End-stage pancreatic cancer currently has no specific treatment, but surgery, radiation, and chemotherapy can extend patients' survival. This article summarizes various targeted therapies for pancreatic cancer, including the use of inhibitors and monoclonal antibodies.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2022)
Article
Multidisciplinary Sciences
Vinay Srinivasan, Stacey E. Weinstein, Azra Bhimani, Nathan C. Clemons, Melissa Dinolfo, Christina S. Shin, Jacqueline Grier, Antonio Lopez, Jamia Braggs, Joni Boucher, Quanna N. Batiste, Omai B. Garner, Shangxin Yang, Tara Vijayan
Summary: This study aimed to evaluate the effectiveness of COVID-19 monoclonal antibody therapies and their susceptibility to variants and vaccinations. The results showed that only selective monoclonal antibody therapies significantly reduced emergency visits, hospitalizations, and deaths related to COVID-19. Vaccination diminished the effectiveness of the treatments.
Article
Oncology
Christopher T. Cummings, Weihe Zhang, Kurtis D. Davies, Gregory D. Kirkpatrick, Dehui Zhang, Deborah DeRyckere, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp, Douglas K. Graham
MOLECULAR CANCER THERAPEUTICS
(2015)
Article
Cell Biology
Paola Maycotte, Suraj Aryal, Christopher T. Cummings, Jacqueline Thorburn, Michael J. Morgan, Andrew Thorburn
Article
Cell Biology
Michael J. Morgan, Graciela Gamez, Christina Menke, Ariel Hernandez, Jacqueline Thorburn, Freddi Gidan, Leah Staskiewicz, Shellie Morgan, Christopher Cummings, Paola Maycotte, Andrew Thorburn
Article
Oncology
Christopher T. Cummings, Deborah DeRyckere, H. Shelton Earp, Douglas K. Graham
CLINICAL CANCER RESEARCH
(2013)
Article
Chemistry, Medicinal
Jing Liu, Weihe Zhang, Michael A. Stashko, Deborah DeRyckere, Christopher T. Cummings, Debra Hunter, Chao Yang, Chatura N. Jayakody, Nancy Cheng, Catherine Simpson, Jacqueline Norris-Drouin, Susan Sather, Dmitri Kireev, William P. Janzen, H. Shelton Earp, Douglas K. Graham, Stephen V. Frye, Xiaodong Wang
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2013)
Article
Chemistry, Medicinal
Weihe Zhang, Dehui Zhang, Michael A. Stashko, Deborah DeRyckere, Debra Hunter, Dmitri Kireev, Michael J. Miley, Christopher Cummings, Minjung Lee, Jacqueline Norris-Drouin, Wendy M. Stewart, Susan Sather, Yingqiu Zhou, Gregory Kirkpatrick, Mischa Machius, William P. Janzen, H. Shelton Earp, Douglas K. Graham, Stephen V. Frye, Xiaodong Wang
JOURNAL OF MEDICINAL CHEMISTRY
(2013)
Article
Chemistry, Medicinal
Weihe Zhang, Deborah DeRyckere, Debra Hunter, Jing Liu, Michael A. Stashko, Katherine A. Minson, Christopher T. Cummings, Minjung Lee, Trevor G. Glaros, Dianne L. Newton, Susan Sather, Dehui Zhang, Dmitri Kireev, William P. Janzen, H. Shelton Earp, Douglas K. Graham, Stephen V. Frye, Xiaodong Wang
JOURNAL OF MEDICINAL CHEMISTRY
(2014)
Article
Oncology
Sandra Christoph, Deborah DeRyckere, Jennifer Schlegel, J. Kimble Frazer, Lance A. Batchelor, Alesia Y. Trakhimets, Susan Sather, Debra M. Hunter, Christopher T. Cummings, Jing Liu, Chao Yang, Dmitri Kireev, Catherine Simpson, Jacqueline Norris-Drouin, Emily A. Hull-Ryde, William P. Janzen, Gary L. Johnson, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp, Douglas K. Graham
MOLECULAR CANCER THERAPEUTICS
(2013)
Article
Oncology
Nellie K. McDaniel, Christopher T. Cummings, Mari Iida, Justus Hulse, Hannah E. Pearson, Eleana Vasileiadi, Rebecca E. Parker, Rachel A. Orbuch, Olivia J. Ondracek, Noah B. Welke, Grace H. Kang, Kurtis D. Davies, Xiaodong Wang, Stephen Frye, H. Shelton Earp, Paul M. Harari, Randall J. Kimple, Deborah DeRyckere, Douglas K. Graham, Deric L. Wheeler
MOLECULAR CANCER THERAPEUTICS
(2018)
Article
Biochemistry & Molecular Biology
R. M. A. Linger, R. A. Cohen, C. T. Cummings, S. Sather, J. Migdall-Wilson, D. H. G. Middleton, X. Lu, A. E. Baron, W. A. Franklin, D. T. Merrick, P. Jedlicka, D. DeRyckere, L. E. Heasley, D. K. Graham
Article
Oncology
K. E. Ware, T. K. Hinz, E. Kleczko, K. R. Singleton, L. A. Marek, B. A. Helfrich, C. T. Cummings, D. K. Graham, D. Astling, A-C Tan, L. E. Heasley
Article
Pediatrics
Christopher T. Cummings, Victor Ritter, Sherri LeBlanc, Ashley G. Sutton
Summary: The current accepted risk factors have limited ability to identify neonates who subsequently develop hypoglycemia. Most screened infants do not actually develop hypoglycemia. The majority of infants who do develop hypoglycemia can achieve normoglycemia with feeding-based interventions, with only a small percentage requiring intravenous dextrose.
Review
Genetics & Heredity
Christopher T. Cummings, M. Jordan Rowley
Summary: Properly organizing DNA within the nucleus is crucial for normal nuclear functions. CTCF and cohesin play major roles in generating chromatin loops, but the direct impact of these loops on gene expression is still uncertain. While controlled depletion experiments suggest resistance to incomplete deficiencies in CTCF or cohesin, heterozygous human genetic deficiencies highlight the importance of their dosage in genome architecture, cellular processes, animal behavior, and disease phenotypes. Further studies comparing these results to mouse models and clinical patients can provide insights into emerging genetic syndromes.
Article
Genetics & Heredity
Christopher Thomas Cummings, Lois Janelle Starr
Summary: This study presents two brothers with biallelic variants in the GTF2IRD1 gene, which encodes a transcription factor. They exhibit severe neurodevelopmental disability, facial dysmorphology, and pectus excavatum. The findings suggest the identification of a new syndrome and have implications for the molecular etiology of Williams-Beuren syndrome (WBS).
AMERICAN JOURNAL OF MEDICAL GENETICS PART A
(2023)